Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neurobiological, Merz Pharma GmbH and Co. KGaA deal

NTII received a $2.1 million royalty payment from Merz on sales

Read the full 111 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE